x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230724
| Product Information | |
|---|---|
| CAS No. | 914471-09-3 |
| Synonyms | 4-[(3-chloro-4-fluoroanilino)-nitrosomethylidene]-1,2,5-oxadiazol-3-amine, IDO inhibitor |
| Formula | C9H7ClFN5O2 |
| Molecular Weight | 271.6 |
| Target | IDO1 |
| Product Description | INCB024360 analog is an orally available hydroxyamidine and inhibitor of indoleamine 2,3- dioxygenase (IDO1), with an IC50 of 10 nM. It shows little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). INCB024360 analog displays potential immunomodulating and antineoplastic activities. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Store as supplied at or below -20 °C for up to 2 years. Stable in DMSO at -80 °C for up to 6 months. |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
